Equities

Hikma Pharmaceuticals PLC

HIK:LSE

Hikma Pharmaceuticals PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,540.00
  • Today's Change-12.00 / -0.77%
  • Shares traded1.15m
  • 1 Year change-32.87%
  • Beta1.1634
Data delayed at least 20 minutes, as of Feb 06 2026 14:55 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Hikma Pharmaceuticals PLC grew revenues 9.77% from 2.88bn to 3.16bn while net income improved 88.95% from 190.00m to 359.00m.
Gross margin43.65%
Net profit margin11.50%
Operating margin16.68%
Return on assets7.17%
Return on equity15.38%
Return on investment10.75%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Hikma Pharmaceuticals PLC fell by 17.00m. However, the company earned 564.00m from its operations for a Cash Flow Margin of 17.87%. In addition the company used 381.00m on investing activities and also paid 188.00m in financing cash flows.
Cash flow per share1.91
Price/Cash flow per share8.07
Book value per share8.46
Tangible book value per share4.40
More ▼

Balance sheet in USDView more

Hikma Pharmaceuticals PLC has a Debt to Total Capital ratio of 37.92%, a lower figure than the previous year's 46.41%.
Current ratio1.24
Quick ratio0.7174
Total debt/total equity0.6139
Total debt/total capital0.3792
More ▼

Growth rates in USD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 5.95% and 88.00%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.38%
Div growth rate (5 year)10.29%
Payout ratio (TTM)50.13%
EPS growth(5 years)-4.29
EPS (TTM) vs
TTM 1 year ago		30.66
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.